UDN@CHOP/UPENN: transition to sustainability

UDN@CHOP/UPENN:向可持续发展过渡

基本信息

  • 批准号:
    10905924
  • 负责人:
  • 金额:
    $ 35.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-20 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

Undiagnosed diseases and rare diseases occur without respect to age, geography, socioeconomic status or level of education. They are frustratingly hard to define scientifically and to classify, yet rare diseases affect 30 million people in the USA and the undiagnosed are as yet uncounted. Referrals to the CHOP/UPENN UDN reflect a larger catchment area than just the four-state geographical region and reflect the inherent dichotomy of the undiagnosed and rare disease patient populations. Our UDN program has a mature collaborative approach to address the needs of the undiagnosed patient population and we are poised to grow through improved workflows and computational approaches. This application proposes three Aims to serve additional patients beyond the expectation of our original allocation. Aim 1 describes our overall diagnostic approach and changes we will implement in enrollment and evaluation workflows. In Aim 2, we describe new diagnostic strategies, focusing on improved bioinformatics. In Aim 3, we describe our long term sustainability plans and transition to this new model. We have been seeing patients in the Clinical and Translational Research Center, named Center for Human Phenomic Science (CHPS), which facilitates a standardized approach and we have developed a template for a narrow data capture to more easily define the key phenotypes. The newly envisioned workflow incorporates a tiered approach to diagnostics. Patients will have next generation sequencing, metabolomics, and/or immunology testing prior to being seen, reasoning that some diagnoses can be easily made in this way and thus streamlining the patient experience. Those that remain unsolved will have deep phenotyping and a multi-omics approach to diagnosis. Our Clinical Site has valuable expertise and has been successful in achieving diagnosis for nearly a quarter of the patients. Our future model is informed heavily by our current UDN practices and will additionally incorporate opportunities to streamline genomic analytic methods, interfacing with ongoing efforts at our institutions to incorporate the “omics” mindset more fully into the diagnostic journey. Our sustainability model will also improve diversity, sharing technology infrastructure and computational methods, accelerating outreach and dissemination approaches, and interfacing more widely with the research community for variant and gene validation. We have the promise of institutional funds and are poised to grow our program to accommodate more patients, improve the demographic diversity, improve the patient diagnostic diversity, and use the UDN model to improve clinician proficiancy with technologic approaches to diagnosis.
未确诊的疾病和罕见疾病的发生与年龄、地理、社会经济地位或教育水平无关。令人沮丧的是,它们很难科学地定义和分类,但罕见疾病影响着美国3000万人,而未确诊的人尚未统计。参考CHOP/UPENN UDN反映了比四个州地理区域更大的集水区,并反映了未诊断和罕见疾病患者人群的固有二分法。我们的UDN计划有一个成熟的协作方法来解决未确诊患者群体的需求,我们准备通过改进工作流程和计算方法来实现增长。这项申请提出了三个目标,以服务超过我们原来分配的预期的额外病人。目标1描述了我们的整体诊断方法以及我们将在招募和评估工作流程中实施的变更。在目标2中,我们描述了新的诊断策略,重点是改进的生物信息学。在目标3中,我们描述了我们的长期可持续发展计划和向这种新模式的过渡。我们一直在临床和转化研究中心(名为人类表型科学中心(CHPS))观察患者,该中心促进了标准化方法,我们开发了一个用于窄数据捕获的模板,以更容易地定义关键表型。新设想的工作流程采用了分层诊断方法。患者在就诊前将进行下一代测序、代谢组学和/或免疫学测试,因为可以通过这种方式轻松进行一些诊断,从而简化患者体验。那些尚未解决的问题将有深入的表型分析和多组学诊断方法。我们的临床研究中心拥有宝贵的专业知识,并已成功地为近四分之一的患者进行了诊断。我们未来的模式在很大程度上受到我们目前UDN实践的影响,并将进一步整合简化基因组分析方法的机会,与我们机构正在进行的努力相结合,将“组学”思维更充分地融入诊断过程。我们的可持续发展模式还将改善多样性,共享技术基础设施和计算方法,加速推广和传播方法,并与研究界更广泛地进行变异和基因验证。我们有机构资金的承诺,并准备扩大我们的计划,以容纳更多的患者,改善人口统计学的多样性,提高患者诊断的多样性,并使用UDN模型,以提高临床医生的熟练程度与技术方法的诊断。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel James Rader其他文献

Daniel James Rader的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel James Rader', 18)}}的其他基金

Undiagnosed diseases network clinical site
未确诊疾病网络临床网站
  • 批准号:
    10600336
  • 财政年份:
    2022
  • 资助金额:
    $ 35.6万
  • 项目类别:
Mechanisms by which ABCA7 activity influences Alzheimer's Disease
ABCA7 活性影响阿尔茨海默病的机制
  • 批准号:
    10525795
  • 财政年份:
    2022
  • 资助金额:
    $ 35.6万
  • 项目类别:
Deep Phenotyping of ANGPTL3, ANGPTL4 and ANGPTL8 Human Knockouts and Population Based Studies
ANGPTL3、ANGPTL4 和 ANGPTL8 人类基因敲除的深度表型分析和基于人群的研究
  • 批准号:
    10186801
  • 财政年份:
    2019
  • 资助金额:
    $ 35.6万
  • 项目类别:
Deep phenotyping of ANGPTL3, ANGPTL4 and ANGPTL8 human knockouts and population based studies
ANGPTL3、ANGPTL4 和 ANGPTL8 人类基因敲除的深度表型分析和基于人群的研究
  • 批准号:
    10528964
  • 财政年份:
    2019
  • 资助金额:
    $ 35.6万
  • 项目类别:
Undiagnosed diseases network clinical site
未确诊疾病网络临床网站
  • 批准号:
    10266763
  • 财政年份:
    2018
  • 资助金额:
    $ 35.6万
  • 项目类别:
Deep Phenotyping of Human Knockouts and Population Studies of the APOC3 Pathway
人类基因敲除的深度表型分析和 APOC3 通路的群体研究
  • 批准号:
    9902507
  • 财政年份:
    2017
  • 资助金额:
    $ 35.6万
  • 项目类别:
Structure-Function Analysis of Triglyceride Regulator ApoA-V Using Natural Variants
使用天然变体进行甘油三酯调节剂 ApoA-V 的结构功能分析
  • 批准号:
    10211481
  • 财政年份:
    2016
  • 资助金额:
    $ 35.6万
  • 项目类别:
Structure-Function Analysis of Triglyceride Regulator ApoA-V Using Natural Variants
使用天然变体进行甘油三酯调节剂 ApoA-V 的结构功能分析
  • 批准号:
    10605242
  • 财政年份:
    2016
  • 资助金额:
    $ 35.6万
  • 项目类别:
Structure-Function Analysis of Triglyceride Regulators ApoC-III and ApoA-V Using Natural Variants
使用天然变体对甘油三酯调节剂 ApoC-III 和 ApoA-V 进行结构-功能分析
  • 批准号:
    9306180
  • 财政年份:
    2016
  • 资助金额:
    $ 35.6万
  • 项目类别:
Structure-Function Analysis of Triglyceride Regulators ApoC-III and ApoA-V Using Natural Variants
使用天然变体对甘油三酯调节剂 ApoC-III 和 ApoA-V 进行结构-功能分析
  • 批准号:
    9158709
  • 财政年份:
    2016
  • 资助金额:
    $ 35.6万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.6万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了